Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG
Open Access
- 24 March 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 19 (8), 1119-1126
- https://doi.org/10.1093/neuonc/nox025
Abstract
Radiation with concurrent and adjuvant (6 cycles) temozolomide (TMZ) is the established standard of postsurgical care for newly diagnosed glioblastoma (GBM). This regimen has been adopted with variations, including extending TMZ beyond 6 cycles. The optimal duration of maintenance therapy remains controversial. We performed pooled analysis of individual patient data from 4 randomized trials for newly diagnosed GBM. All patients who were progression free 28 days after cycle 6 were included. The decision to continue TMZ was per local practice and standards, and at the discretion of the treating physician. Patients were grouped into those treated with 6 cycles and those who continued beyond 6 cycles. Progression-free and overall survival were compared, adjusted by age, performance status, resection extent, and MGMT methylation. A total of 2214 GBM patients were included in the 4 trials. Of these, 624 qualified for analysis 291 continued maintenance TMZ until progression or up to 12 cycles, while 333 discontinued TMZ after 6 cycles. Adjusted for prognostic factors, treatment with more than 6 cycles of TMZ was associated with a somewhat improved progression-free survival (hazard ratio [HR] 0.80 [0.65–0.98], P = .03), in particular for patients with methylated MGMT (n = 342, HR 0.65 [0.50–0.85], P < .01). However, overall survival was not affected by the number of TMZ cycles (HR = 0.92 [0.71–1.19], P = .52), including the MGMT methylated subgroup (HR = 0.89 [0.63–1.26], P = .51). Continuing TMZ beyond 6 cycles was not shown to increase overall survival for newly diagnosed GBM.This publication has 35 references indexed in Scilit:
- Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trialThe Lancet Oncology, 2014
- A Randomized Trial of Bevacizumab for Newly Diagnosed GlioblastomaThe New England Journal of Medicine, 2014
- Toxicity Profile of Temozolomide in the Treatment of 300 Malignant Glioma Patients in KoreaJournal of Korean Medical Science, 2014
- Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)Journal of Clinical Oncology, 2013
- Comparison of the effectiveness of MRI perfusion and fluorine-18 FDG PET-CT for differentiating radiation injury from viable brain tumor: a preliminary retrospective analysis with pathologic correlation in all patientsClinical Imaging, 2013
- Prognostic Value of Early [18F]Fluoroethyltyrosine Positron Emission Tomography After Radiochemotherapy in Glioblastoma MultiformeInternational Journal of Radiation Oncology*Biology*Physics, 2011
- Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE StudyJournal of Clinical Oncology, 2010
- Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenograftsNeuro-Oncology, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- A Hypermutation Phenotype and Somatic MSH6 Mutations in Recurrent Human Malignant Gliomas after Alkylator ChemotherapyCancer Research, 2006